TGA / PMDA / NMPA · Asia-Pacific
expansion — TGA / PMDA / NMPA regulatory status
expansion regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 16 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 2023/3668 | Phase 2 | George Institute for | 2023-505925-15-00 |
| 223050 | Phase 2 | GSK Glaxo Smith | 2025-521581-10-00 |
| BB-1701-G000-205 | Phase 2 | Eisai | 2023-506866-30-00 |
| CLIN-01194-450 | Phase 2 | Ipsen | 2023-506228-10-00 |
| CRN09682-191 | Phase 2 | Anaxis Pharma | 2025-521672-60-00 |
| CSET 2022-3571 | Phase 2 | George Institute for | 2023-503606-36-00 |
| LB101-101 | Phase 2 | Centessa Pharmaceuticals | 2023-505576-29-00 |
| TG1-CL-301 | Phase 2 | Anaxis Pharma | 2025-523802-34-00 |
| 20220028 | Phase 1 | Amgen | 2023-509047-26-00 |
| 4010-01-001 | Phase 1 | TESARO Bio Netherlands | 2023-506390-35-00 |
| An Open-Label for Solid tumors and ovarian cancer | Phase 1 | Anaxis Pharma | 2024-512375-12-00 |
| BP45378 | Phase 1 | HOFFMANN-LA ROCHE | 2025-520631-17-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12343380 | Expansion of TILs utilizing AKT pathways inhibitors | US |
| 12031157 | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 12024718 | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 11981921 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | US |
| 11866688 | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 11667890 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion | US |
| 11401506 | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy | US |
| 11384337 | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 11357841 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | US |
| 10760076 | Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion | US |
| 10709812 | Biodegradable hydrogel for tissue expansion | US |
| 10415015 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of expansion?
expansion currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get expansion regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to expansion?
This spoke lists 16 published programs associated with expansion in our pipeline index.